Melinta Therapeutics

Melinta Therapeutics is a company focused on antibiotics. The company's mission is to discover, develop, and commercialize urgently needed breakthrough antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies against drug-resistant infections is widely regarded as one of the most severe public health challenges facing the world today. To meet this demand, Melinta Therapeutics is rapidly advancing its late-stage research antibiotic delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). Additionally, Melinta is committed to its ongoing research programs aimed at developing a new class of antibiotics designed to overcome resistant ESKAPE pathogens, which are known to cause most serious hospital-acquired infections and patient deaths.